

PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Medicar Part D Tafinlar (dabrafenib)

Phone: 800-728-7947

Fax back to: 866-880-4532

Scott & White Prescription Services manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	Prescriber Name:
	Supervising Physician:
Member/Subscriber Number:	Fax: Phone:
Date of Birth:	Office Contact:
Group Number:	NPI: State Lic ID:
Address:	Address:
City, State ZIP:	City, State ZIP:
Primary Phone:	Specialty/facility name (if applicable):

Drug Name and Strength:

Directions / SIG:

Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.

Q1. Indicate whether the patient is a NEW START to Tafinlar or whether this is continuation of established therapy. <input type="checkbox"/> CONTINUATION of Tafinlar therapy <input type="checkbox"/> NEW START to Tafinlar
Q2. For what diagnosis is the drug being prescribed (pick one)? <input type="checkbox"/> Malignant melanoma, unresectable or metastatic <input type="checkbox"/> Other
Q3. Please provide ICD code(s) for diagnosis
Q4. Is prescribing physician an oncology specialist? <input type="checkbox"/> Yes <input type="checkbox"/> No
Q5. Has the presence of BRAF V600E mutation been confirmed by testing? <input type="checkbox"/> Yes <input type="checkbox"/> No

PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Medicar Part D Tafinlar (dabrafenib)

Phone: 800-728-7947 Fax back to: 866-880-4532

Scott & White Prescription Services manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	Prescriber Name: Supervising Physician:
Q6. Has the presence of BRAF V600K mutation been confirmed by testing? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q7. Does the patient have wild-type BRAF melanoma? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q8. Will Tafinlar be used in combination with Mekinist? (If yes, please fill out a separate prior authorization form for Mekinist). <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q9. Additional comments	

Prescriber Signature

Date

Expedited/Urgent - By checking this box and signing above, I certify that applying the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document